Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma

Authors: Mengyan Wu, Yingxia Liu, Xiaoqing Di, Haixian Kang, Hua Zeng, Yi Zhao, Kangrong Cai, Tianyun Pang, Sen Wang, Yunhong Yao, Xinrong Hu

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) is involved in integration and amplification of many carcinogenesis signals in tumors. However, it remains unclear whether eIF4E over-expresses in NPC and whether it is associated with the development of NPC. Here, we analyzed the expression state of eIF4E, c-Myc, and MMP9 in 24 nasopharyngitises and 64 nasopharyngeal carcinomas (NPC) tissues and studied the influences of eIF4E on the proliferation and cell cycle in NPC cell lines. The results indicate that eIF4E might over-express in NPC and the over-expression of eIF4E promotes NPC growth and cell cycle progression through enhancing the translational expression of c-Myc and MMP9. The finding certainly adds new knowledge in the understanding of the carcinogenesis of NPC and provides a potential molecular target for the NPC therapy and prevention.
Literature
1.
go back to reference Joshi B, et al. Characterization of mammalian eIF4E-family members. Eur J Biochem. 2004;271:2189–203.PubMedCrossRef Joshi B, et al. Characterization of mammalian eIF4E-family members. Eur J Biochem. 2004;271:2189–203.PubMedCrossRef
2.
go back to reference Li Y, et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272–80.PubMedCrossRef Li Y, et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272–80.PubMedCrossRef
3.
go back to reference Avdulov S, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 2004;5:553–63.PubMedCrossRef Avdulov S, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 2004;5:553–63.PubMedCrossRef
4.
go back to reference Robalino J, et al. Two zebrafish eIF4E family members are differentially expressed and functionally divergent. J Biol Chem. 2004;279:10532–41.PubMedCrossRef Robalino J, et al. Two zebrafish eIF4E family members are differentially expressed and functionally divergent. J Biol Chem. 2004;279:10532–41.PubMedCrossRef
5.
go back to reference Lazaris-Karatzas A, et al. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature. 1990;345:544–7.PubMedCrossRef Lazaris-Karatzas A, et al. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature. 1990;345:544–7.PubMedCrossRef
6.
go back to reference PolunoVSky VA, et al. The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol. 2006;3:10–7.PubMedCrossRef PolunoVSky VA, et al. The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol. 2006;3:10–7.PubMedCrossRef
7.
go back to reference Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol. 2008;86:178–83.PubMedCrossRef Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol. 2008;86:178–83.PubMedCrossRef
8.
go back to reference Larsson O, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007;67:6814–24.PubMedCrossRef Larsson O, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007;67:6814–24.PubMedCrossRef
9.
go back to reference Flowers A, et al. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery. 2009;146:220–6.PubMedCrossRef Flowers A, et al. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery. 2009;146:220–6.PubMedCrossRef
10.
go back to reference Anthony B, et al. Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines. Int J Cancer. 1996;65:858–63.PubMedCrossRef Anthony B, et al. Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines. Int J Cancer. 1996;65:858–63.PubMedCrossRef
11.
go back to reference Chen CN, et al. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol. 2004;86:22–7.PubMedCrossRef Chen CN, et al. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol. 2004;86:22–7.PubMedCrossRef
12.
go back to reference Wang R, et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer. 2009;66:237–44.PubMedCrossRef Wang R, et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer. 2009;66:237–44.PubMedCrossRef
13.
go back to reference Walsh D, et al. Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines. Differentiation. 2003;71:126–34.PubMedCrossRef Walsh D, et al. Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines. Differentiation. 2003;71:126–34.PubMedCrossRef
14.
go back to reference Sorrells DL Jr, et al. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg. 1999;57:294–9.PubMedCrossRef Sorrells DL Jr, et al. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg. 1999;57:294–9.PubMedCrossRef
15.
go back to reference Nathan CO, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2004;10:5820–7.PubMedCrossRef Nathan CO, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2004;10:5820–7.PubMedCrossRef
17.
go back to reference Oridate N, et al. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther. 2005;4:318–23.PubMedCrossRef Oridate N, et al. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther. 2005;4:318–23.PubMedCrossRef
18.
go back to reference DeFatta RJ, et al. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 2000;110:928–33.PubMedCrossRef DeFatta RJ, et al. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 2000;110:928–33.PubMedCrossRef
19.
go back to reference Abdulamir AS, et al. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. BMC Public Health. 2008;8:400–15.PubMedCrossRef Abdulamir AS, et al. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. BMC Public Health. 2008;8:400–15.PubMedCrossRef
20.
21.
go back to reference Wang XL, et al. Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol. 2012;18:2540–4.PubMedCrossRef Wang XL, et al. Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol. 2012;18:2540–4.PubMedCrossRef
22.
go back to reference Lin CJ, et al. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 2008;68:5326–34.PubMedCrossRef Lin CJ, et al. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 2008;68:5326–34.PubMedCrossRef
23.
go back to reference Fan CS, et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol. 2000;31:169–78.PubMedCrossRef Fan CS, et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol. 2000;31:169–78.PubMedCrossRef
24.
go back to reference Liu Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270–6.PubMedCrossRef Liu Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270–6.PubMedCrossRef
Metadata
Title
EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma
Authors
Mengyan Wu
Yingxia Liu
Xiaoqing Di
Haixian Kang
Hua Zeng
Yi Zhao
Kangrong Cai
Tianyun Pang
Sen Wang
Yunhong Yao
Xinrong Hu
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0400-z

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.